CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug1043 washed microbiota transplantation Wiki 1.00
drug446 Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment Wiki 1.00
drug788 Standard treatment Wiki 0.58
drug1003 placebo Wiki 0.38

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.12
D007239 Infection NIH 0.08

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Isotretinoin in Treatment of COVID-19 (Randomized)

Submitted by Mahmoud Elkazzaz Assessment the Activity Value of 13- cis-Retinoic Acid(Isotretinoin) in the Treatment of COVID-19 Mahmoud ELkazzaz(a),Tamer Haydara(b),Mohamed Abdelaal(c),Ahmed M. Kabel(d),Abedelaziz Elsayed (e)Hesham Attia(f) 1. PI's,Department of chemistry and biochemistry, Faculty of Science, Damietta University,GOEIC,Egypt. 2. SI's,Department of Internal Medicine,Faculty of Medicine, Kafrelsheikh University, Egypt 3. SI's,Department of Cardiothoracic Surgery,Faculty of Medicine, Kafrelsheikh University, Egypt 4. SI's,Department of Clinical Pharmacy, Faculty of Pharmacy, Taif University, Taif, Saudi Arabia. 5. SI's, Department of Pharmaceutical Biotechnology, Faculty of Pharmacy,Tanta University,Egypt. 6. SI's,Department of Immunology and Parasitology,Faculty of Science,Cairo university,Egypt. Roles of the Investigators according to ClinicalTrials.gov: 1. Principal Investigator(PI's): is the Corresponding Author and the Innovative of Protocol Ideas who is responsible for replying any questions related to the Protocol Ideas and Mechanisms and have rights to discuss or publish Trial Results after the Trial is completed as the First Author followed by Sub Investigators as Second, Middle, and Last Authors on future published results. 2. Sub Investigators(SI's): are the Adopters of the Protocol Most of them are experienced and professional Human Doctors and Pharmacists who are familiar with respiratory diseases and drugs interactions and they able to make study-related decisions regarding the diagnosis and treatment of the disease or condition under investigation and they are aware of how to deal with patients, especially patients with the emerging coronavirus, because it is a serious threat and rapidly spreading virus and Also, to make sure there aren't any medication interaction, errors and misuse and they are responsible for applying the methodology section of the Protocol In addition to following upThe Infected Patients and recording Drug side effects ________________________________________________________________________________________ ______________________________________________________ Brief Summary: The COVID-19 pandemic caused by SARS-COV-2 has infected over 2,000,000 people causing over 150,000 deaths.Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 and for which there are currently no approved treatments. Here, the principal investigator reports according to previous studies and research findings that retinoic acid could strongly affect both inflammation and viral entry in severe acute respiratory syndrome (SARS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection via modulating and reducing cytokine storm factors (IL- 6,IL-1,IL-10 and tumor necrosis factors alpha ) which are over expressed in COVID 2019 infection and contribute to disease progression, poor outcomes and poor survival in patients infected with severe acute respiratory syndrome(SARS-CoV-2) and also, via blocking viral entry by inhibition factor which induce Serine protease 2 expression rather than inhibition of ACE2 ,AT1 protein and Ang II-mediated intracellular calcium release pathway which is responsible for SARS-CoV-2 cell fusion and entry as opposed to medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications.Retinoic acid which induce FOXP3 and CD8+,CD4+,CD25+,FOXP3+ Tregs which their absence during acute infection alters the ability of the host to limit tissue damage. and T cells which were dramatically reduced in COVID-19 patients to exert its antiviral and anti-inflammatory effect protecting lung cells and neural cells from the inflammatory and the destructive effect of IL-6. In addition to inducing retinoic acid inducible gene-1 (RIG-1) and endosomal toll-like receptor 3 (TLR3) as pathogen-associated molecular patterns. This recognition resulted in the formation of type-1 interferon (IFN1). As an evasion mechanism, virus synthesize proteins that hinder the production of IFN type1 in COVID 2019 . In adition to its anti-platelet and fibrinolytic activities protecting patients infected with covid 2019 infection from widespread blood clots. Keywords: COVID 2019 , Retinoic acid, Endosomal toll-like receptor 3,T Cells, IFN type1, AT1,ACE2,TMPRSS2,RIG-1.

NCT04353180 COVID19 Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment Drug: Standard treatment

Primary Outcomes

Description: Proportion of lung injury score decreased or increased after treatment

Measure: lung injury score

Time: at 7and 14 days

Secondary Outcomes

Description: lymphocyte counts

Measure: Absolute lymphocyte counts

Time: at day 7 and 14 after randimization

Description: Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon

Measure: Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon

Time: at day 7 and 14 after randimization

Description: Serum level of COVID19 RNA

Measure: Serum level of COVID19 RNA

Time: at day 7 and 14

Description: died

Measure: All cause mortality rate

Time: at day 7 and 14

Description: ventilation free days

Measure: Ventilation free days

Time: at 14 days

Description: ICU free days

Measure: ICU free days

Time: at 14 days

Description: less than 250 ng/mL, or less than 0.4 mcg/mL of blood sample

Measure: d-dimers

Time: at 3-5days

Description: (if pos. at baseline)

Measure: Time to first negative SARS-CoV-2 PCR in NP swap

Time: within 14 days


No related HPO nodes (Using clinical trials)